Alpha Cognition Inc. (Nasdaq: ACOG) ("Alpha Cognition", or the "Company") today announced its financial results for the ...

Zunveyl (benzgalantamine) is now available for the treatment of mild to moderate dementia of the Alzheimer type in adults.

Northwestern Health Sciences University (NWHSU), a leading health sciences university, announced the creation of a major endowed scholarship by The Joint Corp., the nation's largest franchisor of ...

Wellen Park, the #6 top-selling master-planned community in the US, is expanding outdoor recreation this year with the addition of three new parks and approximately 10 miles of nature trails. Located ...

"The launch of ZUNVEYL is a game-changer in our fight against Alzheimer’s disease," said Lauren D’Angelo, COO and chief ...

Zunveyl is supplied as 5mg, 10mg, and 15mg delayed-release tablets, which can be taken with or without food. Zunveyl ® (benzgalantamine) is now available for the treatment of mild to moderate ...

Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced the official commercial launch of ZUNVEYL, a new ...

Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced the official commercial launch of ZUNVEYL ...

Alpha Cognition (ACOG) announced the official commercial launch of ZUNVEYL, a new treatment for mild to moderate Alzheimer’s disease. This ...

The company’s nationwide salesforce is fully deployed and actively engaging with healthcare providers to ensure that ZUNVEYL reaches the patients who need it most. The commercial strategy is ...

The company’s nationwide salesforce is fully deployed and actively engaging with healthcare providers to ensure that ZUNVEYL reaches the patients who need it most. The commercial strategy is ...